Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field. ...read more Source: As schizophrenia rivals rush in, Otsuka and Lundbeck gain FDA OK for Rexulti
